Mark Cuban's Cost Plus Drug Company adds new SGLT2 inhibitor Brenzavvy for type 2 diabetes
Mark Cuban’s Cost Plus Drug Company is bringing another brand-name type 2 diabetes treatment under its wing.
TheracosBio’s recently approved SGLT2 inhibitor Brenzavvy is now available by prescription through Cuban’s Cost Plus Drugs at $47.85 for a 30-day supply, the drugmaker announced Thursday.
“We’ve always wanted to be able to bring this forward on an affordable basis to the type 2 diabetic patient population,” TheracosBio CEO Albert Collinson told Endpoints News. “The simple fact is most people don’t get access to new medications because their health insurance makes it difficult or it’s associated with significant expense.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.